

of the Sequence Listing, a paper copy of the Sequence Listing, a response to the Notice (copy enclosed) with the required statement of identity and no new matter (see below in Section ), an Amendment directing the entry of the Sequence Listing separately into the specification and; 2) An Abstract of the Invention on a separate sheet.

IN THE SPECIFICATION:

Please insert, after page 89, the Abstract on page 90.

Please insert, after the claims, as a separate part, the paper copy of the Sequence Listing.

IN THE CLAIMS:

Please cancel claims 10 and 11.

REMARKS

Reconsideration of the application is respectfully requested in view of the cancellation of claims 10 and 11, the amendments to the specification including the abstract and the Sequence Listing, and the additional remarks that follow. Thus, claims 1-9 and 12-65 are pending.

I. The Amendments

Applicant has cancelled claims 10 and 11. However, Applicant does not acquiesce to the grounds for rejection of claims 10 and 11, and reserves the right to pursue the subject matter in a later continuing application. Therefore, as a result of the cancellation, claims 1-9 and 12-65 are presently pending. Applicant acknowledges that the Examiner has indicated that all the pending claims are allowed.

II. The Abstract

The Examiner has requested that an abstract on a separate sheet be submitted. Applicant has provided the requested abstract as indicated on page 90.

III. The Sequence Listing

Applicant acknowledges the requirement to comply with the Notice to Comply, a copy of which is enclosed. In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825, enclosed is a Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is a copy of the Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Sequence Listing is labeled SHIH.APP.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821 - §1.825, are the same and that no new matter has been added.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

IV. Rejection under 35 U.S.C. §102(b)

Claims 10 and 11 were rejected under 35 U.S.C. §102(b) as being respectively anticipated by Danon (EMBO, 10:3993-4001 (1991)) and Danon (EMBO, 13:2227-2235 (1994)).

Applicant has canceled claims 10 and 11 without acquiescing to the grounds for rejection and reserves the right to pursue the subject matter in a later continuing application. In view of the cancellation of claims 10 and 11, Applicant submits that the present rejection is now moot.

V. Summary

Applicant believes to have fully addressed all material issues and objections recited in the Office Action. Therefore, Applicant respectfully requests that the rejections be withdrawn and that all the pending claims be passed on to allowance. Should any matters remain which might be

Serial No.: 09/341,550  
January 19, 2000

4

TSRI 578.2

resolved via telephone, however, the examiner is courteously invited to contact the undersigned at the number given below.

Respectfully submitted,

Dated: 1/10/00

By: Emily Holmes  
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road  
Mail Drop TPC 8  
La Jolla, California 92037  
(858) 784-2937

☒ [X] Attorney or agent of record  
☐ [ ] Filed under §1.34a

Patentserv\Shared\Emily\wp\oa\scr2177p.res